Acorda Therapeutics Provides Update on Clinical Development of ...
Business Wire (press release) - San Francisco,CA,USA
... on feedback it received in a meeting with the US Food and Drug
Administration (FDA), it will design and conduct an additional Phase
3 trial of Fampridine-SR in ...

2006 - A Very Good Year in MS Research
PR Newswire (press release) - New York,NY,USA
... The FDA approved the return to market of Tysabri(R)
(natalizumab ... Since Tysabri's return to market last summer
there have been no new cases of PML reported. ...

MS drug unlikely to gain OK for Crohn's
Boston Globe - United States
... executive, James Mullen, says the Cambridge biotechnology
company is unlikely to receive approval from European regulators
to use its drug Tysabri to treat ...
See all stories on this topic

Dismay over MS treatment decision
BBC News - UK
Both the MS Society and the MS Trust believe the drug
Tysabri could help slow the progression of disability in hundreds
of sufferers. ...
See all stories on this topic

Monday's Analysts' Upgrades and Downgrades
TheStreet.com - USA
... Stock is up 15% since the strong third quarter earnings report.
Tysabri also unlikely to see accelerated sales in the near-term,
based on channel checks. ...

Acordia Plans Added Trial
TheStreet.com - USA
Acorda Therapeutics (ACOR - commentary - Cramer's Take) plans an additional Phase 3 trial of its Fampridine-SR drug in people with multiple sclerosis. ...

Acorda to conduct additional MS drug trial
BusinessWeek - USA
In September 2006, the company said its Fampridine-SR MS drug improved the ... completed under a Special Protocol Assessment with the FDA, meaning Acorda sat down ...

Acorda Calls for 2 More Trials
Motley Fool - USA
... On Friday, Acorda updated investors on the progress of its MS drug, named Fampridine-SR. As expected, the FDA is requiring another ...

UPDATE1-Acorda to conduct additional Phase III trial for MS drug
Reuters - USA
... In September, the company had reported positive data from its earlier late-stage trial of the drug, Fampridine-SR. Acorda Therapeutics said the FDA requires ...

Market Report -- In Play (ACOR)
MSN Money - USA
Acorda Therapeutics announces it will design and conduct an additional Phase 3 trial of Fampridine-SR in people with MS Co confirmed that, based on feedback it ...

Acorda Therapeutics (ACOR) To Conduct Additional Phase 3 Trial for ...
StreetInsider.com (subscription) - Birmingham,MI,USA
Acorda Therapeutics, Inc. ... based on feedback it received in a meeting with the FDA, it will design and conduct an additional Phase 3 trial of Fampridine-SR in ...

Roche presents yet more promising data on MabThera
Pharma Times (subscription) - London,UK
... addition of rituximab to CVP confers long-term benefit. ... has shown promise in various other indications, notably rheumatoid arthritis and multiple sclerosis. ...

2006 - A Very Good Year in MS Research
PR Newswire (press release) - New York,NY,USA
... of the year include: * Acorda Therapeutics (Hawthorne, NY) announced positive results of a Phase 3, placebo-controlled clinical trial of Fampridine-SR, an oral ...

Drug maker sees room for change in federal approach
Boston Globe - United States
For Biogen Idec Inc., the return of the multiple sclerosis drug Tysabri to the market and continued sales growth for its cash cow, Avonex, were the highlights ...

Hawthorne-based Acorda Therapeutics will continue testing MS drug
The Journal News.com - Westchester,NY,USA
The company said it decided to continue testing the drug, Fampridine-SR, based on feedback it received from the US Food and Drug Administration. ...